+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The low-density lipoprotein cholesterol-lowering effect of pravastatin and factors associated with achieving targeted low-density lipoprotein levels in an African-American population



The low-density lipoprotein cholesterol-lowering effect of pravastatin and factors associated with achieving targeted low-density lipoprotein levels in an African-American population



Pharmacotherapy 20(12): 1454-1463



Study Objectives. To describe the low-density lipoprotein cholesterol (LDL)-lowering effect of pravastatin in African-American patients and to identify factors associated with achieving National Cholesterol Education Program (NCEP)-defined target levels. Design. Retrospectively defined cohort study. Setting. Large, government-owned, teaching hospital. Patients. Eighty-four African-American patients starting therapy with pravastatin in October-November 1997. Interventions. None. Measurements and Main Results. Whether or not target LDL concentrations were achieved was used to measure efficacy. Stepwise logistic regression identified the target LDL, baseline LDL, and baseline high-density lipoprotein cholesterol (HDL) as significant predictors of achieving the target. The proportion of patients achieving their target LDL when that target was below 160, below 130, and 100 mg/dl or below was 64%, 32%, and 13% (p=0.004), respectively. Medical record review identified the reasons for not achieving target as incorrect drug regimen, inadequate lipid monitoring, and noncompliance. Conclusion. These results indicate that substantial numbers of patients receiving lipid-lowering therapy are not meeting NCEP-defined targets and that with increased drug monitoring and compliance, improvements in achieving NCEP target LDL levels could be realized.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011523363

Download citation: RISBibTeXText

PMID: 11130218

DOI: 10.1592/phco.20.19.1454.34855


Related references

Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism: Clinical and Experimental 54(6): 741-747, 2005

Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. European Heart Journal 25(9): 771-777, 2004

Pravastatin reduces major coronary events in patients with low levels of both high-density lipoprotein cholesterol and low-density lipoprotein cholesterol Results from the LIPID Study. Journal of the American College of Cardiology 37(2 Supplement A): 262A, 2001

Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology 90(7): 731-736, 2002

Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. Journal of the American College of Cardiology 55(1): 35-41, 2010

Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol: The Very Large Database of Lipids Study (VLDL-2B). Circulation 132(8): 667-676, 2015

Environmental factors, familial aggregation and heritability of total cholesterol, low density lipoprotein-cholesterol and high density lipoprotein-cholesterol in a Brazilian population assisted by the Family Doctor Program. Public Health 125(6): 329-337, 2011

Effect of food on the low density lipoprotein cholesterol lowering response to twice daily pravastatin. Arteriosclerosis 8(5): 590A-591A, 1988

High density lipoprotein and metabolic risk factors of ischemic heart disease in men aged up to 50 years part i. high density lipoprotein cholesterol high density lipoprotein triglycerides high density lipoprotein phospholipids and phospholipid fractions in dyslipidemias. Zywienie Czlowieka I Metabolizm 13(1): 26-37, 1986

Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. Metabolism: Clinical and Experimental 58(4): 568-575, 2009

ZD4522 is superior to pravastatin and simvastatin in reducing low density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low density lipoprotein cholesterol guidelines. Journal of the American College of Cardiology 37(2 Supplement A): 291A, 2001

Effect of addition of exercise to therapeutic lifestyle changes diet in enabling women and men with coronary heart disease to reach Adult Treatment Panel III low-density lipoprotein cholesterol goal without lowering high-density lipoprotein cholesterol. American Journal of Cardiology 89(10): 1201-1204, 2002

Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and concentrations of plasma lipids with high-density lipoprotein subclass distribution in the Chinese population. Lipids in Health and Disease 9: 69, 2010

Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. American Journal of Cardiology 80(7): 831-835, 1997

High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Yearbook of Endocrinology 2012: 72-74, 2012